The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.

Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data Patients with stage I-III colon cancer treated with upfront ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in ...

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in ...

Tecentriq plus chemotherapy reduced recurrence or death risk by 50% in stage III colorectal cancer with deficient mismatch repair. The combination therapy achieved a 3-year disease-free survival rate ...

When Vanessa was diagnosed with advanced colon cancer in 2014, just before her 60th birthday, the mother and grandmother learned the cancer had already spread to her stomach and liver. Even after a ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have ...